Case Reports Open access

Prostatic artery embolization for intractable hematuria in patients with unregulated coagulation parameters: three case reports

Authors

Published
9 May 2024
Section
Case Reports
DOI
10.4081/aiua.2024.12306

Abstract

Introduction: Benign prostatic hyperplasia is a prevalent disease that could be responsible of severe intractable hematuria requiring invasive surgical management.
Case presentation: We report three high-risk cases presented with intractable hematuria of prostatic origin with high medical co-morbidities treated safely and effectively by prostatic artery embolization with favorable outcomes.
Conclusions: In non-surgical, anticoagulated patients, prostatic artery embolization represents a safe and effective intervention for the treatment of intractable hematuria related to benign prostatic hyperplasia.

Keywords

References

  1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984; 132:474-9. DOI: https://doi.org/10.1016/S0022-5347(17)49698-4
  2. Ramyil VM, Dakum NK, Liman HU, Udeh EI. The management of prostatic haematuria. Niger J Med. 2008; 17:439-42. DOI: https://doi.org/10.4314/njm.v17i4.37429
  3. Elzayat EA, Elhilali MM. Holmium laser enucleation of the prostate (HoLEP): the endourologic alternative to open prostatectomy. Eur Urol. 2006; 49:87-91. DOI: https://doi.org/10.1016/j.eururo.2005.08.015
  4. Elzayat E, Habib E, Elhilali M. Holmium laser enucleation of the prostate in patients on anticoagulant therapy or with bleeding disorders. J Urol. 2006; 175:1428-32. DOI: https://doi.org/10.1016/S0022-5347(05)00645-2
  5. DeMeritt JS, Elmasri FF, Esposito MP, Rosenberg GS. Relief of benign prostatic hyperplasia-related bladder outlet obstruction after transarterial polyvinyl alcohol prostate embolization. J Vasc Interv Radiol. 2000; 11:767-70. DOI: https://doi.org/10.1016/S1051-0443(07)61638-8
  6. Kuang M, Vu A, Athreya S. A Systematic Review of Prostatic Artery Embolization in the Treatment of Symptomatic Benign Prostatic Hyperplasia. Cardiovasc Intervent Radiol. 2017; 40:655-663. DOI: https://doi.org/10.1007/s00270-016-1539-3
  7. Tian W, Zhou C, Leng B, et al. Prostatic Artery Embolization for Control of Gross Hematuria in Patients with Benign Prostatic Hyperplasia: A Single-Center Retrospective Study in 20 Patients. J Vasc Interv Radiol. 2019; 30:661-667. DOI: https://doi.org/10.1016/j.jvir.2019.02.008
  8. Mohan S, Kumar S, Dubey D, et al. Superselective vesical artery embolization in the management of intractable hematuria secondary to hemorrhagic cystitis. World J Urol. 2019; 37:2175-2182. DOI: https://doi.org/10.1007/s00345-018-2604-0
  9. Kearney MC, Bingham J, Bergland R, et al. Clinical predictors in the use of finasteride for control of gross hematuria due to benign prostatic hyperplasia. J Urol. 2002; 167:2489-2491. DOI: https://doi.org/10.1016/S0022-5347(05)65011-2
  10. Hanson RA, Zornow MH, Conlin MJ, Brambrink AM. Laser resection of the prostate: implications for anesthesia. Anesth Analg. 2007; 105:475-9. DOI: https://doi.org/10.1213/01.ane.0000270217.82825.1f
  11. Feng S, Tian Y, Liu W, et al. Prostatic Arterial Embolization Treating Moderate-to-Severe Lower Urinary Tract Symptoms Related to Benign Prostate Hyperplasia: A Meta-Analysis. Cardiovasc Intervent Radiol. 2017; 40:22-32. DOI: https://doi.org/10.1007/s00270-016-1516-x
  12. Abt D, Hechelhammer L, Müllhaupt G, et al. Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: randomised, open label, non-inferiority trial. BMJ. 2018; 361:k2338. DOI: https://doi.org/10.1136/bmj.k2338
  13. Carnevale FC, Moreira AM, Antunes AA. The "PErFecTED technique": proximal embolization first, then embolize distal for benign prostatic hyperplasia. Cardiovasc Intervent Radiol. 2014; 37:1602-5. DOI: https://doi.org/10.1007/s00270-014-0908-z

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.

PlumX Metrics

License

Copyright (c) 2024 the Author(s)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.